Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients

IF 3.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-04-01 DOI:10.1016/j.aohep.2025.101815

Kevin S. Vázquez-Hernández , Andres Burak-Leipuner , Alfredo I. Servin-Caamaño , Javier A. Romero-Bermúdez , Laura E. Ceceña-Martínez , José L. Pérez-Hernández , María C. Castañeda-Aguilar , Fátima Higuera-de la Tijera

{"title":"Prevalence of fibrosis and steatosis determined by transient elastography and controlled attenuation parameter (Fibroscan®) in diabetic patients","authors":"Kevin S. Vázquez-Hernández , Andres Burak-Leipuner , Alfredo I. Servin-Caamaño , Javier A. Romero-Bermúdez , Laura E. Ceceña-Martínez , José L. Pérez-Hernández , María C. Castañeda-Aguilar , Fátima Higuera-de la Tijera","doi":"10.1016/j.aohep.2025.101815","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Globally, a higher prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has been reported in diabetics (55.5%) compared to the general population (25%). In Mexico, there is a lack of studies on diabetes (DM2) in this subgroup. Objective: To determine the prevalence of hepatic fibrosis and steatosis determined by FibroScanâ in patients with DM2.</div></div><div><h3>Materials and Patients</h3><div>An observational, descriptive, cross-sectional study included patients who attended the clinic for DM2 between August 2018 and March 2024 and underwent FibroScan® to determine the absence/presence and degree of fibrosis and steatosis. Patients were excluded if they had risky alcohol consumption, hepatitis B/C, any type of previously diagnosed hepatopathy or cirrhosis, or consumption of medications other than those for metabolic syndrome (MS). Descriptive statistics were used, and the prevalence of FibroScan® determined steatosis and fibrosis was estimated.</div></div><div><h3>Results</h3><div>A total of 298 patients were evaluated, 195 (64.5%) women, with a mean age of 55.6±10.8 years. Of these, 284 (95.3%) agreed to undergo FibroScan® examination, none had risky alcohol consumption, 146 (51.4%) were smokers, 114 (40.1%) were overweight, 75 (25.6%) had grade I obesity, 34 (12%) had grade II obesity, and 14 (4.9%) had grade III obesity. 106 (56.3%) were hypertensive, 177 (62.3%) had dyslipidemia, and 168 (59.2%) met the criteria for MS. Regarding the FibroScan® parameters, 109 (38.4%) had steatosis: S1 in 34 (12%), S2 in 33 (11.6%), and S3 in 42 (14.8%). There was fibrosis in 155 (56.4%): F1 in 42 (14.8%), F2 in 40 (14.1%), F3 in 26 (9.2%), and F4 in 47 (16.5%). The biochemical parameters of this cohort are shown in Table 1. There was no relationship between the duration of DM2, the stage of disease control, recent adherence to treatment, and the presence or stage of steatosis or fibrosis (p=N.S.).</div></div><div><h3>Conclusions</h3><div>The prevalence of MASLD associated steatosis and fibrosis is high in Mexican diabetic patients and occurs independently of disease control, disease duration, and recent adherence to treatment.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101815"},"PeriodicalIF":3.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268125000390","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objectives

Globally, a higher prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has been reported in diabetics (55.5%) compared to the general population (25%). In Mexico, there is a lack of studies on diabetes (DM2) in this subgroup. Objective: To determine the prevalence of hepatic fibrosis and steatosis determined by FibroScanâ in patients with DM2.

Materials and Patients

An observational, descriptive, cross-sectional study included patients who attended the clinic for DM2 between August 2018 and March 2024 and underwent FibroScan® to determine the absence/presence and degree of fibrosis and steatosis. Patients were excluded if they had risky alcohol consumption, hepatitis B/C, any type of previously diagnosed hepatopathy or cirrhosis, or consumption of medications other than those for metabolic syndrome (MS). Descriptive statistics were used, and the prevalence of FibroScan® determined steatosis and fibrosis was estimated.

Results

A total of 298 patients were evaluated, 195 (64.5%) women, with a mean age of 55.6±10.8 years. Of these, 284 (95.3%) agreed to undergo FibroScan® examination, none had risky alcohol consumption, 146 (51.4%) were smokers, 114 (40.1%) were overweight, 75 (25.6%) had grade I obesity, 34 (12%) had grade II obesity, and 14 (4.9%) had grade III obesity. 106 (56.3%) were hypertensive, 177 (62.3%) had dyslipidemia, and 168 (59.2%) met the criteria for MS. Regarding the FibroScan® parameters, 109 (38.4%) had steatosis: S1 in 34 (12%), S2 in 33 (11.6%), and S3 in 42 (14.8%). There was fibrosis in 155 (56.4%): F1 in 42 (14.8%), F2 in 40 (14.1%), F3 in 26 (9.2%), and F4 in 47 (16.5%). The biochemical parameters of this cohort are shown in Table 1. There was no relationship between the duration of DM2, the stage of disease control, recent adherence to treatment, and the presence or stage of steatosis or fibrosis (p=N.S.).

Conclusions

The prevalence of MASLD associated steatosis and fibrosis is high in Mexican diabetic patients and occurs independently of disease control, disease duration, and recent adherence to treatment.

查看原文本刊更多论文

糖尿病患者瞬时弹性成像和控制衰减参数（Fibroscan®）测定的纤维化和脂肪变性患病率

在全球范围内，与普通人群（25%）相比，糖尿病患者（55.5%）的代谢功能障碍相关脂肪肝（MAFLD）患病率更高。在墨西哥，缺乏对该亚组糖尿病（DM2）的研究。目的：探讨纤维扫描法测定DM2患者肝纤维化和脂肪变性的发生率。材料和患者：一项观察性、描述性、横断面研究纳入了2018年8月至2024年3月期间因DM2就诊的患者，并接受了FibroScan®检查，以确定纤维化和脂肪变性的存在和程度。如果患者有危险饮酒、乙型/丙型肝炎、任何类型的先前诊断的肝病或肝硬化，或服用代谢综合征（MS）以外的药物，则排除在外。采用描述性统计，并估计FibroScan®确定的脂肪变性和纤维化的患病率。结果共纳入298例患者，其中女性195例（64.5%），平均年龄（55.6±10.8）岁。其中，284人（95.3%）同意接受FibroScan®检查，没有人有危险饮酒，146人（51.4%）是吸烟者，114人（40.1%）超重，75人（25.6%）患有I级肥胖，34人（12%）患有II级肥胖，14人（4.9%）患有III级肥胖。106例（56.3%）患有高血压，177例（62.3%）患有血脂异常，168例（59.2%）符合ms标准。根据FibroScan®参数，109例（38.4%）患有脂肪变性：S1例34例（12%），S2例33例（11.6%），S3例42例（14.8%）。155例（56.4%）有纤维化，F1 42例（14.8%），F2 40例（14.1%），F3 26例（9.2%），F4 47例（16.5%）。该队列的生化指标见表1。DM2持续时间、疾病控制阶段、近期坚持治疗与脂肪变性或纤维化的存在或分期之间没有关系（p=N.S.）。结论墨西哥糖尿病患者MASLD相关脂肪变性和纤维化的患病率较高，且与疾病控制、病程和近期治疗依从性无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.